IMUNON’s IMNN-001 Shows Promising Results for Advanced Ovarian Cancer: New Data Highlights Extended Survival and Durable Responses
IMNN-001 Data Reveals Notable Survival Gains in Phase 2 Trials
IMUNON, Inc. (NASDAQ:IMNN) recently unveiled fresh translational findings for its leading immunotherapy, IMNN-001, designed for women with advanced ovarian cancer. Presented at the AACR Special Conference in Cancer Research, the new data from the OVATION 2 study showcases why IMNN-001 could represent a game-changing option for this high-need patient group.
IMNN-001 utilizes a unique gene-mediated delivery platform—TheraPlas®—which triggers the local production of interleukin-12 (IL-12) within the tumor microenvironment. This approach is intended to supercharge anti-cancer immune activity, turning a 'cold' tumor microenvironment into a 'hot' one that is more susceptible to treatment.
Clinical Results Underscore Potential: Median Survival Benefits and Durable Responses
The OVATION 2 randomized Phase 2 study (n=112) delivered several noteworthy outcomes for patients who received IMNN-001 in combination with standard-of-care chemotherapy:
| Efficacy Measure | IMNN-001 Arm | Standard Care Arm | Hazard Ratio (HR) |
|---|---|---|---|
| Median Overall Survival (OS) | 13 months longer (not yet reached with PARP inhibitor maintenance) | 37 months (with PARP inhibitor maintenance) | 0.42 (with PARP inhibitors), 0.70 overall |
| Median Progression-Free Survival (PFS) | 3 months longer | - | 0.79 |
| Total Time Free of Progression or Death (PFS + OS) | 6.5 months extension (p=0.0375) | - | - |
Of special note, the use of poly ADP-ribose polymerase (PARP) inhibitors during maintenance therapy further enhanced overall survival. In the IMNN-001 arm, median overall survival has not yet been reached for these patients—even after five years from trial randomization—while standard-of-care reached 37 months. This kind of durable response highlights the immunotherapy’s long-term potential when layered on top of current treatments.
Pipeline Advances: OVATION 3 Phase 3 Trial Progresses with Expanded Sites
The new data lends significant support to the ongoing OVATION 3 pivotal Phase 3 trial. This study continues to enroll women with advanced epithelial ovarian cancer at four active sites, with as many as 46 more being evaluated for activation. Given the consistent benefits shown in prior studies—extending both progression-free and overall survival—the momentum heading into the next phase is substantial.
The technology behind IMNN-001 is also central to IMUNON’s strategy. By using non-viral, DNA-based immunotherapies to harness the immune system, the company aims to provide safe, durable, and effective responses not just for ovarian cancer, but for other solid tumors in the future. IMUNON’s platform further includes PlaCCine®, a gene-based vaccine technology for infectious diseases, currently in early-stage studies.
What This Means for Investors and Patients
For those following oncology innovation, the IMNN-001 program offers a rare combination: solid clinical progress, biologically rational design, and early signals of meaningful patient benefit. While interim results always carry caveats—such as the challenge of extrapolating early survival data—this new release puts IMUNON on the radar for upcoming clinical and regulatory milestones.
The next catalyst to watch: further enrollment updates from the OVATION 3 Phase 3 trial and additional presentations at high-profile cancer meetings. If durability trends persist, IMNN-001 could reshape the landscape for treating advanced ovarian cancer, especially for patients not well-served by today’s standards of care.
Contact Information
| Media | Investors |
|---|---|
| Jenna Urban, CG life 212-253-8881 jurban@cglife.com |
Peter Vozzo, ICR Healthcare 443-213-0505 peter.vozzo@icrhealthcare.com |
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI